Across TCGA pan-cancer cohorts, CTNNAL1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CTNNAL1 data layer compared with 25 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CTNNAL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CTNNAL1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.
CCRCC, LUAD, and LSCC are the cancer types where CTNNAL1 mass-spec protein most reproducibly stratifies survival.